Target: CD7.
Clone: T3-3A1.
Specificity: Clone T3-3A1 recognizes an epitope on human CD7.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: CD7 is expressed on T cells, NK cells, thymocytes, hematopoietic progenitors, some normal B cells, malignant B cells, acute lymphocytic leukemia (ALL) cells, and some acute myeloid leukemia (AML) cells. It is weakly expressed on monocytes.
Background: CD7 is a 40 kD type I transmembrane glycoprotein and is a member of the Ig superfamily. It plays a vital role in T-cell interactions, in adition to, T-cell/B-cell interaction during early lymphoid development, and has been shown to interact with PIK3R1. Functional studies indicate that crosslinking of the CD7 can stimulate transmembrane calcium flux in T cells. Lack of CD7 expression can help to diagnose T-cell lymphoproliferative disorders, such as mycosis fungoides/Sezary syndrome and adult T-cell leukemia/lymphoma.
Concentration: 1.0 – 5.0 mg/ml.
Formulation: This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and azide free.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
